Controlled study on the effect of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease
Regional cerebral blood flow (rCBF) in 90 patients with CBF decreased due to vascular diseases was studied by using the xenon 133 inhalation technique and a 32-detector setup. Whereas 30 patients received their standard basic therapy only and were regarded as controls, 30 others received 3 x 2 mg/day of an ergot alkaloid (co-dergocrine mesylate), and 30 others received 3 x 400 mg pentoxifylline (slow-release formulation)/day orally. Therapy was performed for eight weeks and CBF measured before start of treatment, after a four-week treatment period, and at the end of the study. CBF did not change significantly in the control group; both the pentoxifylline and the ergot alkaloid group presented with a significant increase in the CBF. This positive effect was significantly more pronounced in the pentoxifylline group and affected more ischemic than other brain tissues. In addition, symptoms like sleep disturbances, vertigo, and tinnitus improved significantly during the pentoxifylline observation period.
- Research Organization:
- Neurologische Universitaetsklinik Bonn (Germany, F.R.)
- OSTI ID:
- 6953816
- Journal Information:
- Angiology; (United States), Journal Name: Angiology; (United States) Vol. 39:5; ISSN ANGIA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Effect of ergot alkaloids associated with fescue toxicosis on hepatic cytochrome P450 and antioxidant proteins
Ergot alkaloid consumption alters serotonin receptor-induced vasoactivity in ovine umbilical vasculature
Related Subjects
59 BASIC BIOLOGICAL SCIENCES
ALKALOIDS
AROMATICS
AZAARENES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
BLOOD FLOW
BODY
BRAIN
CARDIOVASCULAR AGENTS
CENTRAL NERVOUS SYSTEM
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
EVEN-ODD NUCLEI
HETEROCYCLIC COMPOUNDS
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
NERVOUS SYSTEM
NUCLEI
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANIC OXYGEN COMPOUNDS
ORGANS
PATHOGENESIS
PATIENTS
PURINES
RADIOISOTOPES
THEOBROMINE
TRACER TECHNIQUES
VASCULAR DISEASES
VASOCONSTRICTORS
VASODILATORS
XANTHINES
XENON 133
XENON ISOTOPES